According to the Cancer Genome Atlas (TCGA), gastric cancers are classified into four
molecular subtypes: Epstein–Barr virus-positive (EBV+), tumors with microsatellite instability …

Despite progress in cancer immunotherapy, ovarian cancer (OC) prognosis continues to be
disappointing. Recent studies have shed light on how not just tumour cells, but also the …

Ovarian high‐grade serous carcinoma (HGSC) originates in the fallopian tube, with
secretory cells carrying a TP53 mutation, known as p53 signatures, identified as potential …

While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous
recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and …

Anti-tumor immunity is crucial for high-grade serous ovarian cancer (HGSC) prognosis, yet
its adaptation upon standard chemotherapy remains poorly understood. Here, we conduct …

Fatty acids are known to have significant effects on the properties of cancer cells. Therefore,
these compounds have been incorporated into therapeutic strategies. However, few studies …

Borderline ovarian tumors (BOTS) are rare neoplasms of intermediate aggressiveness
between cystadenomas and low-grade ovarian cancers (lgOvCa), which they share some …

Patients with metastatic ovarian cancer (OvCa) have a 5-year survival rate of< 30% due to
the persisting dissemination of chemoresistant cells in the peritoneal fluid and the …

Shallow genome-wide cell-free DNA (cfDNA) sequencing holds great promise for non-
invasive cancer monitoring by providing reliable copy number alteration (CNA) and …

Induction of senescence by chemotherapeutic agents arrests cancer cells and activates
immune surveillance responses to contribute to therapy outcomes. In this investigation, we …